Quanterix Corp SEC Filings

Quanterix Corp filed an initial ownership report for Chief Commercial Officer Benjamin Meadows, outlining his equity-based compensation. Meadows holds 76,234 stock options with an exercise price of $5.88 per share, expiring on October 6, 2035, vesting 25% after one year and the rest in 36 monthly installments.

He was granted 22,959 restricted stock units on October 6, 2025 with 25% vesting after one year and the remaining 75% in 36 monthly installments. On February 15, 2026, he received 70,223 restricted stock units vesting 25% per year for four years, and 70,223 performance stock units that may vest in four equal annual installments once performance conditions under the 2026 Employee Equity Guidelines are met.

Quanterix Corporation reported the results of its 2026 annual shareholder meeting held on June 9, 2026. Stockholders elected William P. Donnelly and Ivana Magovčević-Liebisch, Ph.D., J.D. as independent directors for one-year terms and approved the advisory vote on executive compensation.

Shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. However, they did not approve an amendment and restatement of the 2017 Employee, Director and Consultant Equity Incentive Plan that would have extended the plan through June 9, 2031.

Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer and Treasurer, with employment expected to begin on June 22, 2026. He brings senior finance leadership experience from Bruker Corporation, PAREXEL, EMC and Harvard Business Publishing, with a background in strategic planning and operational finance.

Under an employment agreement dated May 31, 2026, Faessler will receive an initial annual base salary of $475,000, a $200,000 cash sign-on bonus, and is eligible for an annual performance bonus targeted at up to 50% of base salary. He will also receive restricted stock units equal to 0.30% of Quanterix’s outstanding common shares on his start date, vesting in four equal annual installments.

If his employment is terminated without Cause or he resigns for Good Reason, Faessler is entitled to 12 months of base salary continuation, a pro-rated target bonus, and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, he also receives full vesting of outstanding unvested equity awards.

Quanterix Chief Technology Officer Michael Francis Miller reported the vesting of 130 restricted stock units, which converted into the same number of common shares on May 31, 2026. 39 of these shares were withheld at $3.06 per share to cover tax obligations, and he now directly holds 33,795 Quanterix common shares. The restricted stock units are part of a 6,278-unit grant from September 23, 2022 that vests 25% after one year and the remaining 75% in 36 equal monthly installments.

Quanterix Corporation appointed Anthony Catalano as its new Chief Operating Officer effective May 14, 2026. He brings prior leadership experience from Flagship Pioneering, Akoya Biosciences, Bruker Cellular Analysis and Revvity.

Under his employment agreement, Catalano will receive a $400,000 annual base salary, a $50,000 cash sign-on bonus and eligibility for an annual performance bonus targeted at up to 50% of base salary. He also received restricted stock units equal to 0.30% of Quanterix common shares outstanding on his start date, vesting in four equal annual installments.

If the company terminates him without Cause or he resigns for Good Reason, he is entitled to six months of base salary continuation, a pro-rated target bonus for the year of termination and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, salary continuation extends to nine months and all outstanding time-based equity awards become fully vested. Michael Miller, the former Chief Operating Officer, has moved to the role of Chief Technology and Products Officer.

Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units (RSUs). On May 15, 2026, RSUs converted into common stock in several tranches, including 1,056, 514, and 263 shares, reflecting scheduled vesting.

To cover tax obligations, the filing shows share dispositions of 315, 154, and 79 shares of common stock at $2.75 per share, characterized as tax-withholding transactions rather than open-market sales. Following these transactions, the CFO directly held 28,897 shares of Quanterix common stock, while additional RSUs remain outstanding and continue to vest over time.

Quanterix Corp Chief Technology Officer Michael Francis Miller reported routine equity compensation activity. On May 15, 2026, restricted stock units vested and were converted into 1,558 shares of Common Stock, while 467 shares were withheld at $2.75 per share to cover tax obligations. After these transactions, he directly owned 32,694 Common shares and 760 restricted stock units that may vest later.

Quanterix Corp Schedule 13G/A amendment shows Portolan Capital Management, LLC and George McCabe beneficially own 2,945,823 shares of Quanterix Common Stock, representing 6.25% of the class. The filing lists sole voting and dispositive power of 2,945,823 shares for each Reporting Person. The cover identifies CUSIP 74766Q101 and the principal business address for the Reporting Persons as 2 International Place, FL 26, Boston, MA 02110. The statement is signed by George McCabe on 05/15/2026.

Ameriprise Financial, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting shared voting and dispositive power over 3,542,374 shares of Quanterix Corp common stock (CUSIP 74766Q101), representing 7.5% of the class. The filing states that AFI disclaims beneficial ownership of the shares reported and incorporates the cover‑page rows by reference.